Pharmaceuticals
-
Merck Eyes Incyte for Possible Acquisition
Merck (MRK) is rumored to be pursuing Incyte (INCY), prompting market volatility.
-
Inside the Market Dominance of the Top 10 Pharma Giants
From innovation to influence. The world's biggest pharma players aren't just leaders. They're industry giants. This infographic shows their...
-
Evotec Receives Takeover Bid from Halozyme (HALO)
Evotec has received a takeover offer from Halozyme, potentially creating a major player in life sciences. Retail investors should watch for market...
-
NTRA Stock: Impressive Growth and Rising Profit Margins
Natera's impressive Q3 2024 highlights its strong position in the genetic testing market.
-
Global Fungal Outbreaks Surge
Fungal outbreaks are increasing globally, impacting health systems and creating new investment opportunities in antifungal research and treatments.
-
INGR Stock: Ingredion Targets Growth in Specialty Ingredients Market
Learn how specialty ingredients leader Ingredion is driving growth and targeting new markets in the consumer staples sector.
-
BMY Breaking New Ground in Schizophrenia Treatment
Bristol Myers Squibb's Cobenfy, the first new schizophrenia treatment in over 70 years, offers hope for patients and investment potential for the...
-
Viridian Therapeutics: A Biotech Tapping High-Growth Potential
See how Viridian Therapeutics (NASDAQ: VRDN) is innovating thyroid eye disease treatments with advanced therapies and a growing market opportunity.
-
Billion-Dollar Market Potential for Targeted Cancer Therapies
Radiopharmaceuticals are revolutionizing cancer treatment, attracting billions in investments. Discover the potential and challenges for investors...
-
Roche Shares Tumble After Obesity Drug Data
Roche's stock dropped 4.5% due to gastrointestinal side effects from its obesity drug CT-388, raising concerns among investors about the drug's...
-
Rising GLP-1 Medication Use to Drive Employer Healthcare Costs
Discover the financial impact of rising GLP-1 medication usage on employer healthcare costs and its relevance for retail investors.
-
Johnson & Johnson Proposes $6.48 Billion Settlement for Talc Lawsuits
Discover why Johnson & Johnson's $6.48 billion talc settlement matters for retail investors: stock impact, legal risks, governance insights,...
-
CARGO Therapeutics Inc (NASDAQ: CRGX) Q2 Results
CARGO Therapeutics reported Q2 2024 results with a slight EPS miss and higher-than-expected R&D expenses, while maintaining a strong cash position.
-
Novo Nordisk Stock Drops on Profit Forecast Revision
Novo Nordisk faces stock drop and competition pressures. Revenue growth vs. profit forecast. Political scrutiny and market strategy in focus.
-
Eli Lilly's Zepbound Shows Promise in Heart Failure Patients
Eli Lilly's Zepbound & Novo Nordisk's Wegovy show health benefits beyond weight loss, influencing investment strategies in pharmaceutical stocks.
-
Viking Therapeutics Accelerates Weight Loss Drug Development
Viking Therapeutics' fast-tracked weight loss injection could reshape the market, impacting investors' portfolios and strategies.
